Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases.

Pazyar N, Feily A, Yaghoobi R.

Curr Clin Pharmacol. 2012 Nov;7(4):271-5. Review.

PMID:
22794157
2.

[Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases].

Lipsker D, Lenormand C.

Ann Dermatol Venereol. 2012 Jun;139(6-7):459-67. doi: 10.1016/j.annder.2012.03.012. Epub 2012 Apr 17. Review. French.

PMID:
22721478
3.

Dermal interleukin-1 expression and effective and long-lasting therapy with interleukin-1 receptor antagonist anakinra in Schnitzler syndrome.

Volz T, Wölbing F, Fischer J, Braun M, Maggoschitz I, Schaller M, Berneburg M, Biedermann T.

Acta Derm Venereol. 2012 Jul;92(4):393-4. doi: 10.2340/00015555-1307. No abstract available.

4.

Treating inflammation by blocking interleukin-1 in humans.

Dinarello CA, van der Meer JW.

Semin Immunol. 2013 Dec 15;25(6):469-84. doi: 10.1016/j.smim.2013.10.008. Epub 2013 Nov 23. Review.

5.

[Update in interleukin-1 inhibition].

de Boysson H.

Rev Med Interne. 2012 Apr;33(4):235-7. doi: 10.1016/j.revmed.2012.01.012. Epub 2012 Feb 22. French. No abstract available.

PMID:
22360831
6.

Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret®) in a case of refractory Sweet's syndrome.

Kluger N, Gil-Bistes D, Guillot B, Bessis D.

Dermatology. 2011;222(2):123-7. doi: 10.1159/000326112. Epub 2011 Apr 5.

PMID:
21464561
7.

Anakinra: an effective treatment in the Schnitzler syndrome.

Vandenhende MA, Bentaberry F, Morlat P, Bonnet F.

Joint Bone Spine. 2011 Dec;78(6):636-7. doi: 10.1016/j.jbspin.2011.03.021. Epub 2011 May 6.

PMID:
21550281
8.

Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.

Koné-Paut I, Galeotti C.

Expert Rev Clin Immunol. 2015;11(10):1083-92. doi: 10.1586/1744666X.2015.1077702. Epub 2015 Aug 27. Review.

PMID:
26312542
9.

Homeostatic tissue responses in skin biopsies from NOMID patients with constitutive overproduction of IL-1β.

Aubert P, Suárez-Fariñas M, Mitsui H, Johnson-Huang LM, Harden JL, Pierson KC, Dolan JG, Novitskaya I, Coats I, Estes J, Cowen EW, Plass N, Lee CC, Sun HW, Lowes MA, Goldbach-Mansky R.

PLoS One. 2012;7(11):e49408. doi: 10.1371/journal.pone.0049408. Epub 2012 Nov 30.

10.

[Schnitzler syndrome: case report, the experience with glucocorticoid and anakinra (Kineret) therapies and monitoring of systemic cytokine response].

Szturz P, Adam Z, Klabusay M, Fojtík Z, Kadanka Z, Stehlíková O, Chovancová J, Kalvodová L, Corbová D, Starý K, Neubauer J, Prásek J, Koukalová R, Rehák Z, Hájek R, Mayer J.

Vnitr Lek. 2011 Jan;57(1):97-112. Czech.

PMID:
21351669
11.

Schnitzler syndrome: response to anakinra in two cases and a review of the literature.

Schuster C, Kränke B, Aberer E, Arbab E, Sturm G, Aberer W.

Int J Dermatol. 2009 Nov;48(11):1190-4. doi: 10.1111/j.1365-4632.2009.04151.x. Review.

PMID:
20064173
12.

Schnitzler syndrome: treatment failure to rituximab but response to anakinra.

Eiling E, Möller M, Kreiselmaier I, Brasch J, Schwarz T.

J Am Acad Dermatol. 2007 Aug;57(2):361-4. Epub 2007 Apr 30.

PMID:
17467852
13.

Rilonacept in the treatment of chronic inflammatory disorders.

McDermott MF.

Drugs Today (Barc). 2009 Jun;45(6):423-30. doi: 10.1358/dot.2009.45.6.1378935. Review.

PMID:
19649332
14.

The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.

Kalliolias GD, Liossis SN.

Expert Opin Investig Drugs. 2008 Mar;17(3):349-59. doi: 10.1517/13543784.17.3.349 . Review.

PMID:
18321234
15.

Successful use of anakinra to treat refractory Schnitzler's syndrome.

Dybowski F, Sepp N, Bergerhausen HJ, Braun J.

Clin Exp Rheumatol. 2008 Mar-Apr;26(2):354-7.

PMID:
18565263
16.

Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra.

Hawkins PN, Lachmann HJ, Aganna E, McDermott MF.

Arthritis Rheum. 2004 Feb;50(2):607-12.

17.

Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens.

Kuemmerle-Deschner JB, Wittkowski H, Tyrrell PN, Koetter I, Lohse P, Ummenhofer K, Reess F, Hansmann S, Koitschev A, Deuter C, Bialkowski A, Foell D, Benseler SM.

Arthritis Res Ther. 2013;15(3):R64.

18.

Effect of in vitro and in vivo anakinra on cytokines production in Schnitzler syndrome.

Launay D, Dutoit-Lefevre V, Faure E, Robineau O, Hauspie C, Sobanski V, Hachulla E, Labalette M, Hatron PY, Dubucquoi S.

PLoS One. 2013;8(3):e59327. doi: 10.1371/journal.pone.0059327. Epub 2013 Mar 19.

19.

[Muckle-Wells syndrome caused by a new cryopyrin mutation: effective treatment with interleukin-1 antagonist].

Rameev VV, Kozlovskaia LV, Bogdanova MV.

Ter Arkh. 2012;84(6):53-9. Russian.

PMID:
22997920
20.

"Mutation negative" familial cold autoinflammatory syndrome (FCAS) in an 8-year-old boy: clinical course and functional studies.

Hedrich CM, Bruck N, Paul D, Hahn G, Gahr M, Rösen-Wolff A.

Rheumatol Int. 2012 Sep;32(9):2629-36. doi: 10.1007/s00296-011-2019-3. Epub 2011 Jul 22.

PMID:
21833523
Items per page

Supplemental Content

Write to the Help Desk